Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
laquebuena941.univision.com
Here is the link for insert-text-here
Suppose to be something going on in dallas with pompis
If anyone can read this, translate it for all;
¡Participa para ser Miss Pompis Dallas del mes!
¡Participa para ser Miss Pompis Dallas del mes!
Fecha: 01/04/2011
Compártelo Enviar Imprimir
Pompis
- Univision.com
FOTO Miss Pompis Dallas
Ver fotos Por: Lorena Flores
Univision.com
¡Tú puedes ser la elegida!
¿Eres alegre, energética y te gusta modelar? ¿Te gustaría ser Miss Pompis Dallas del mes? Entonces esta puede ser tu gran oportunidad.
Llévate tu lata de pompis a cualquier lugar del Metroplex, luce tu mejor ángulo, posa junto a la lata y podrías ser elegida la ganadora del mes y hacerte acreedora a un premio en efectivo de $500.00, una sesión fotografía y obviamente el titulo de ser Miss Pompis del Mes en Dallas.
Envía tus fotos desde ya y pronto podrás ver la galería de las participantes, los visitantes de la página de La Que Buena 94.1 eligieran a una ganadora con sus votos y otra afortunada será elegida por el panel de jueces de la estación.
Más detalles.
Puedes mandar una, dos o tres fotos, con tu nombre, edad, dirección y teléfono al correo electrónico: Misspompisdallas@univision.com
Revisa las reglas oficiales para más detalles.
¡Esperamos ya tus fotos! ¡Tu puedes ser Miss Pompis del Mes de Dallas!
Aviso
Al enviarnos un correo electrónico con contenido, estás otorgando a Univision Communications, Inc., y a todas sus entidades, una licencia no exclusiva para transmitir, publicar, emitir, distribuir, editar, exhibir, promocionar, grabar, poner a disposición en la red o de otra forma explotar comercialmente el contenido a través de cualesquiera y todas formas, medios, procesos y tecnologías ya sea conocida en el presente o que se desarrollen en el futuro en perpetuidad a través del universo. También, representas y garantizas de que eres el propietario del contenido que subirás y que el ejercicio de los derechos aquí otorgados no infringirá ni violará, directa o indirectamente, ningún derecho de persona o entidad alguna.
Reglas Oficiales
Reglas Oficiales del Concurso
Backside Beverages LLC
Pompis
4560 Beltline Suite 350
Addison, Texas 75001
NO SE REQUIERE COMPRA O PAGO DE CUALQUIER TIPO PARA GANAR.
Concurso en línea Miss Pompis
Fecha (s) de promoción: 1ro de abril ??del 2011 - 29 de abril del 2011
Los ganadores serán seleccionados en o alrededor del 29 de abril 2011
El ganador tendrá 30 días para reclamar el premio
Los participantes pueden participar enviando fotografías por correo electrónico a Univision.com
Debe tener por lo menos 18 años de edad el o antes del 29 de abril. Debe ser residente legal.
Dos ganadores serán seleccionados: (1ro) voto en línea (2 do) seleccionara representante de Univision Radio
Premio (s): (por ganador) $ 500 + Sesión de Fotografía Professional proporcionada por el Patrocinador y la oportunidad se la Chica Pompis del Mes
Personas en cualquiera de las siguientes categorías no podrán participar ni ganar un premio: (a) personas que a partir del primer día de la promoción hayan sido o sean empleados o agentes del Patrocinador o la empresa matriz, subsidiarias o filiales o agencias de servicio o contratistas independientes de la organización(es) mencionada(s), (b) personas que estén involucradas en el desarrollo, producción, distribución de materiales, o en la sección de los ganadores de este sorteo, y (c) personas que son familia inmediata de, o que residen en la misma casa de alguna persona en cualquiera de las categorías anteriores.
El Patrocinador no se hace responsable por fotografías participantes perdidas o mal dirigidas. Todos los participantes están de acuerdo con permitir que el Patrocinador utilice su nombre, dirección, ciudad, estado, voz, video o cualquier semejanza con fines publicitarios o de publicidad sin compensación adicional alguna. El Patrocinador puede utilizar la información presentada por los participantes para ofrecerles información sobre otras ofertas, productos o servicios.
Un total de dos ganadores serán seleccionados - (1) a través de votos en línea (2) representante de Univision Radio. Los ganadores serán notificados por medio de correo electrónico. La decisión del Patrocinador será final y obligatoria en todos los aspectos. Cada ganador y cada invitado del ganador que sea permitido participar en el premio podrán ser obligados a firmar una liberación de responsabilidad. Si el ganador no es elegible, se considerara que el ganador ha rechazado el premio y el Patrocinador seleccionará a un nuevo ganador. Para reclamar los premios, los ganadores deberán presentar una identificación aceptable al Patrocinador y recoger premios como sean instruidos. Ganador(es) no están autorizados a sustituir los premios no monetarios por su equivalente en efectivo. El Patrocinador se reserva el derecho de sustituir cualquiera o todos los premios con cualquier artículo o servicio de valor semejante o mayor a su entera discreción. Los premios no podrán ser cedidos o transferidos por los ganadores. Para la lista de ganador(es) de premios, disponibles a partir de que termine la promoción, envíe un sobre por separado, con su dirección y el sello a "Concurso - Lista de ganadores" a la dirección antes mencionada. Los impuestos (federales, estatales y locales) son responsabilidad exclusiva del ganador y puede ser necesario que el ganador llene formularios de impuestos.
Al participar, los solicitantes están de acuerdo: (a) estar sujetos a las Reglas Oficiales y las decisiones del Patrocinador, y (b) liberar y eximir al Patrocinador y sus filiales, estaciones, subsidiarias, y contratistas independientes, y sus respectivos directores, funcionarios, empleados y agentes, incluyendo agencias de publicidad y promoción, de cualquier y toda responsabilidad con respecto a la aceptación, posesión o uso (o mal uso) de los premios o en la participación en el sorteo.
Backside Beverages LLC
Pompis
4560 Beltline Suite 350
Addison, Texas 75001
NO PURCHASE OR PAYMENT OF ANY KIND IS NECESSARY TO WIN.
Miss Pompis Online Contest
Promotional Date(s): April1, 2011 – April 29, 2011
Winners will be selected on or about April 29, 2011
Winner will have 30 days to collect prize
Participants can enter by sending pictures via email to Univision.com
Must be a least 18 years of age on or before 4/29. Must be legal resident.
2 winners will be selected: (1st ) online voting (2nd) Univision Radio representative selects
Prize(s): (Per winner) $500 + Professional Photo Session provided by Sponsor and P Opportunity to be Pompis Girl of the Month
Persons in any of the following categories are not eligible to participate or win a prize: (a) persons who from and after the first day of the giveaway were or are employees or agents of Sponsor or Sponsor’s parent, subsidiaries or affiliates or the service agencies or independent contractors of the above organization(s); (b) persons who are engaged in the development, production, distribution of materials, or drawing of winners for this giveaway; and (c) persons who are immediate family of or who reside in the same household as any person in either of the preceding categories.
Sponsor is not responsible for any lost or misdirected photo submissions. All participants agree to permit Sponsor to use his/her name, address, city, state, voice, videotape or any likeness for advertising or publicity purposes for no additional compensation. Sponsor may use information submitted by participants to offer them information on other offers, products or services.
A total of 2 winners will be selected - (1) via online votes (2) Univision Radio representative. Winners will be notified via email notification. Sponsor's decision will be final and binding in all respects. Each winner and each guest of the winner permitted to participate in the prize may be required to sign liability releases. If a winner is ineligible, the winner will be deemed to have rejected the prize and Sponsor will select a new winner. To claim prizes, winners will be required to provide identification acceptable to Sponsor and to pick up prizes as instructed. Winner(s) are not permitted to substitute non-cash prizes for their cash equivalent. Sponsor reserves the right to substitute any or all of the prizes with any article or service of similar or greater value at its sole discretion. Prizes may not be assigned or transferred by winners. For the list of the prize-winner(s), available after the giveaway ends, send a separate, self-addressed stamped envelope to "Giveaway - List of Winners" to the above address. Taxes (federal, state, and local) are the sole responsibility of the winner and the winner may be required to complete tax forms.
By participating, registrants agree: (a) to be bound by the Giveaway Official Rules and the decisions of Sponsor, and (b) to release and hold harmless Sponsor and their affiliates, stations, subsidiaries, and independent contractors, and their respective directors, officers, employees, and agents, including advertising and promotion agencies, from any and all liability with respect to acceptance, possession or use (or misuse) of the prizes or participation in the giveaway.
© 2011 Univision Communications Inc.
Someone be liking this stock today
172,000 shares bought at $3.85
AVI BioPharma Prices $30.0 Million Public Offering of Common Stock
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Friday 1 April 2011
AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it has priced an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.50 per share for gross proceeds of $30.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by the Company, will be approximately $27.8 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any, which would result in additional gross proceeds of $4.5 million if exercised in full.
The Company currently intends to use the net proceeds from this offering for general corporate purposes, including research and product development, such as funding clinical trials, pre-clinical studies and otherwise moving product candidates towards commercialization. The offering is expected to close on or about April 6, 2011, subject to the satisfaction of customary closing conditions. Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as joint book-running managers and ThinkEquity LLC is acting as co-manager for the offering. Wedbush PacGrow Life Sciences acted as a financial advisor to the Company for the offering.
A shelf registration statement (File No. 333-160922) relating to these securities was filed on July 31, 2009 and declared effective by the Securities and Exchange Commission on August 13, 2009. A preliminary prospectus supplement related to the offering was filed with the Securities and Exchange Commission. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering can be obtained at the Securities and Exchange Commission's website http://www.sec.gov or from Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (800) 542-0970 or by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or via telephone at (800) 747-3924.
Item 8.01 Other Events.
On March 31, 2011, AVI BioPharma, Inc. (the "Company") issued a press release announcing an offering of its common stock. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein.
The Company intends to propose at its 2011 Annual Meeting of Shareholders that the shareholders approve an equity incentive plan authorizing the issuance of awards with respect to up to approximately 15,000,000 shares of the Company's common stock.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been filed with the Securities and Exchange Commission:
Exhibit Number Description
99.1 Press release dated March 31, 2011.
trouble in paradise this afternoon here on avii
AVI BioPharma Announces Proposed Public Offering of Common Stock
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 31 March 2011
AVI BioPharma, Inc. (NASDAQ: AVII) today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company currently intends to use the net proceeds from this offering for general corporate purposes, including research and product development, such as funding clinical trials, pre-clinical studies and otherwise moving product candidates towards commercialization. The offering is expected to price before 9:30 am EDT on Friday April 1, 2011.
Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
The Company intends to offer and sell these securities pursuant to the Company's existing shelf registration statement (File No. 333-160922) filed with the Securities and Exchange Commission on July 31, 2009, which was declared effective on August 13, 2009. A prospectus supplement describing the terms of the offering will be filed with the Securities and Exchange Commission and will form a part of the effective registration statement. When available, copies of the preliminary prospectus supplement, the final prospectus supplement and accompanying base prospectus related to this offering may be obtained from the Securities and Exchange Commission's website at http://www.sec.gov or Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (800) 542-0970 or by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or via telephone at (800) 747-3924.
This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of the Company, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking, including statements about AVI's financing plans and prospects, including the statements about the proposed public offering of AVI's common stock. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
to hold and see, not worth the chance
so is the stock
It be lookin nice
whoah we have a little life
Pompis on 4 Wheels
Pompis On 4 Wheels
AVI BioPharma Names Peter S. Linsley, Ph.D., Chief Scientific Officer
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Monday 28 March 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief Scientific Officer effective May 1, 2011. The addition of Dr. Linsley, who is recognized industry-wide for his groundbreaking RNA- and microRNA-focused research as well as his work in advancing scientific discoveries into clinical development, is a continuation of AVI's strategy to assemble a world-class executive leadership team.
Prior to joining AVI, Dr. Linsley, 59, was Chief Scientific Officer of Regulus Therapeutics, a biopharmaceutical company created as a joint venture of Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., to focus on the discovery and development of drug candidates that target microRNAs. While at Regulus, Dr. Linsley led the company's research and development efforts and built a scientific base for some of the first strategic transactions in the microRNA therapeutic arena. Before this, he was Executive Director of Cancer Biology at Merck Research Laboratories, where he led efforts to implement RNA interference technologies that culminated in Merck's 2007 acquisition of Sirna Therapeutics, Inc. Dr. Linsley originally joined Merck when the company acquired Rosetta Inpharmatics, LLC, where he held a variety of positions, including Vice President of Research and Development. Earlier in his career, Dr. Linsley was Director of Immunology at Bristol-Myers Squibb (BMS). At BMS he co-discovered the co-stimulatory pathway, a discovery that yielded the immunomodulatory drugs abatacept (Orencia) and belatacept and, most recently, the anticancer drug ipilimumab (Yervoy).
"Peter's rare combination of RNA-specific thought-leadership and drug discovery expertise positions him to play an integral role in establishing AVI's PMO-based chemistry as a leading medical technology," said Garabedian. "We welcome Peter to our team as we look to expand and advance our pipeline of morpholino drug candidates to target a variety of disease areas."
Dr. Linsley commented, "I believe that AVI is well-positioned to turn good science and unique technology into a portfolio of RNA-based drugs that are safe, effective and easy to administer. I believe AVI's morpholino oligonucleotide technology, known as PMO, is at the forefront of the development of what are potentially transformative RNA-based therapeutics and presents a number of exciting and significant opportunities that would not be open to other technologies. I look forward to helping harness the potential of the PMO chemistry across a range of therapeutic opportunities."
Dr. Linsley conducted postdoctoral research in the department of Genetics at the Hospital for Sick Children in Toronto. He earned his Ph.D. at the Molecular Biology Institute of the University of California, Los Angeles, and a bachelor's degree in Biology from Auburn University, where he graduated magna cum laude. In addition to participating on the editorial boards of several scientific journals, including the Journal of Immunology, Dr. Linsley has published more than 200 scientific articles and has led discoveries that are protected by more than 35 issued U.S. patents.
via facebook: Some lovely ladies in Dallas-Ft Worth will be sharing their Pompis with everyone at the Harry Hines Bazaar both Saturday and Sunday from 2 pm to 6 pm, and in the Univision pavilion at Trader Village from noon to 4 pm on Saturday. Come get you some!!!
And what do we owe this beautiful volume and movement to
interesting
thats awesome brantpoint
very quiet here, whats going to happen here
Anyone home
Great Job Bama, Thanks for the Updates
And what does that mean to the wave?
wow took me 3 days, finally got my shares
Thanks Bama Awesome
Awesome Volume today, hope it means something isa brewin
EI Ship me a can of pompis :)
Sure looks like someone is very interested in this stock, nice size blocks being bought up
EI, DId you expect this type of quick movment up ? Whats the feeling on it?
gotto love the early action
impressive rally there at the end
Left Behind Games = perfect name for the stock after today
got to love it
wow its like it just shutdown now, 116 mill to nothin
I dont understand, Why the big sell off this morning, what did i miss? Thought report was good,
.0021 x .0022 vol 98 mill
buy order 4.6 mill at .002
From what iam told, no, EI can answer that better